Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
46-60 of 474
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Project Oncology®Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Lajos Pusztai, MD, DPhil
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Project Oncology®Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Shelina Ramnarine, PhD
Mohamed Abdelbaki, MD
- advertisement
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Project Oncology®Exploring Combination Treatment in ER+/HER2- Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP
Wassim Mchayleh, MD, MBA, FACP
Supporting Patients Throughout Urothelial Carcinoma Treatment
Project Oncology®Supporting Patients Throughout Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Project Oncology®Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Project Oncology®3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Alexandria May, PharmD, BCPS
Daniel Landi, MD
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Project Oncology®What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Petros Grivas, MD, PhD
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CME/CECELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
Sagar Lonial, MD, FACP
- advertisement
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Project Oncology®Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Shelina Ramnarine, PhD
John Mascarenhas, MD
Marina Kremyanskaya, MD
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Project Oncology®Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Charles Turck, PharmD, BCPS, BCCCP
Douglas A. Tremblay, MD
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Project Oncology®Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Steve Jackson, PharmD
Apar Kishor Ganti, MD
Thomas Marron, MD, PhD